The Justice Department accused the drugmakers of offering or paying money to entice health plan beneficiaries to buy their drugs.
“Pharmaceutical companies undercut a key safeguard against rising drug costs when they create assistance funds to serve as conduits for the companies to subsidize the copays of their own drugs,” said Assistant Attorney General Jody Hunt of the Department of Justice’s Civil Division. “These enforcement actions make clear that the government will hold accountable drug companies that directly or indirectly pay illegal kickbacks.”
Federal prosecutors are more aggressively pursuing drugmakers for donating to programs that provide patients with free medication or copay assistance. Most recently, Novartis paid $23 million to settle claims it used charities to pay kickbacks to Medicare patients to cover their out-of-pocket costs. Alexion Pharmaceuticals also disclosed it paid $13 million to resolve claims concerning payments to patient organizations.
More articles on pharmacy:
7 drugs projected to become blockbusters by 2023
3 insulin manufacturers to testify at House panel April 10
Cigna-Express Scripts cap out-of-pocket 30-day insulin costs at $25
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.